1. Scrip
  2. >>Business
  3. >>Deals

Roche/Genentech Keeps Commitment To External Cancer Innovation

Interview: Oncology Partnering’s Don O’Sullivan, Genentech R&D’s Shiva Malek

 
• By Mandy Jackson

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Business consulting with expert help and financial advice tiny person concept
Virtual dealmaking due to COVID-19 did not slow Roche's oncology partnering progress • Source: Shutterstock

Roche Holding AG/Genentech, Inc. global oncology partnering head Don O’Sullivan is eager to get back to the days of discussing deals in person over a glass of wine, but noted in an interview that the COVID-19 pandemic did not slow his business development group’s progress in accessing external innovation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.